

| | | | | | |
|---|--|---------------------|------|-----------|------|
| Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa K, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Hidenori Toyoda, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, <u>Kudo M</u> | FGF3/FGF4 Amplification and Multiple lung Matastases in responders to sorafenib in hepatocellular carcinoma. | Hepatolog y | 57 | 1407-1415 | 2013 |
| Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi K, Katsushima S, <u>Kudo M</u> , Takaguchi K, Hiasa Y, Chayama K, Yatsunami H, Oketani M, Kumada H | Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. | J Gastroent erol | 48 | 382-390 | 2013 |
| Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study Group of Japan | Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. | Liver Int | 33 | 762-770 | 2013 |
| Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, <u>Kudo M</u> , Mochizuki T | Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. | Radiology | 266 | 480-490 | 2013 |
| Hagiwara S, <u>Kudo M</u> , Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada Y, Nishida N | Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. | J Med Virol | 85 | 987-95 | 2013 |
| <u>Kudo M</u> | Early Hepatocellular Carcinoma: Definition and Diagnosis. | Liver Cancer | 2(2) | 69-72 | 2013 |
| Matsui S, Kashida H, <u>Kudo M</u> | Senile systemic amyloidosis localized to the stomach. | Digest Endosc | 25 | 468-469 | 2013 |

| | | | | | |
|--|---|-----------------------|----|-----------|------|
| Mine H, Sakurai T, Kashida H, Matsui S, Nishida N, Nagai T, Hagiwara S, Watanabe T, <u>Kudo M</u> | Association of gankyrin and stemness factor expression in human colorectal cancer. | Dig Dis Sci | 58 | 2337-2344 | 2013 |
| Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, <u>Kudo M</u> , Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y | A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization. | Eur J Cancer | 49 | 2832-2840 | 2013 |
| Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H, <u>Kudo M</u> | Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. | World J Gastroenterol | 19 | 5706-5712 | 2013 |
| <u>Kudo M</u> | [Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013. | Digest Dis | 31 | 405-407 | 2013 |
| Nishida N, Iwamura S, Ida H, Hagiwara S, Kagioka Y, Minami Y, Maetani Y, Itoh K, <u>Kudo M</u> | Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases. | Digest Dis | 31 | 408-414 | 2013 |
| Yada N, <u>Kudo M</u> , Chung H, Watanabe T | Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis. | Digest Dis | 31 | 415-420 | 2013 |
| Sugimoto K, Kim SR, Shamy AE, Imoto S, Ando K, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Takashi H, Hotta H, Hayashi Y, <u>Kudo M</u> | Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance. | Digest Dis | 31 | 421-425 | 2013 |
| Kim SR, Shamy AE, Imoto S, Kim KI, Sugimoto K, Kim SK, Tanaka Y, Hatae T, Hasegawa Y, Fujinami A, Ohta M, Hotta H, <u>Kudo M</u> | Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load. | Digest Dis | 31 | 426-433 | 2013 |
| Sugimoto K, Kim SR, Shamy AE, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, <u>Kudo M</u> | Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy. | Digest Dis | 31 | 434-439 | 2013 |
| Sakurai T, <u>Kudo M</u> , Watanabe T, Itoh K, Higashitsuji H, Arizumi T, Inoue T, Hagiwara S, Ueshima K, Nishida N, Fukumoto M, Fujita J | Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production. | Digest Dis | 31 | 440-446 | 2013 |

| | | | | | |
|---|--|------------|----|---------|------|
| Nishida N, <u>Kudo M</u> | Oxidative stress and epigenetic instability in human hepatocarcinogenesis. | Digest Dis | 31 | 447-453 | 2013 |
| Kim SK, Marusawa H, Eso Y, Chiba T, <u>Kudo M</u> | Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations. | Digest Dis | 31 | 454-458 | 2013 |
| Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, <u>Kudo M</u> | Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. | Digest Dis | 31 | 459-466 | 2013 |
| Tsuji N, Ishiguro S, Sasaki Y, <u>Kudo M</u> | CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. | Digest Dis | 31 | 467-471 | 2013 |
| Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, <u>Kudo M</u> | Hypovascular hepatic nodules showing hypointense on the hepatobiliary phase image of Gd-EOB-DTPA enhanced MRI to develop a hyper-vascular hepatocellular carcinoma: a nationwide retrospective study on their Natural course and Risk factors. | Digest Dis | 31 | 472-479 | 2013 |
| Minami Y, Hayaishi S, <u>Kudo M</u> | Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding? | Digest Dis | 31 | 480-484 | 2013 |
| Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Hori M, <u>Kudo M</u> , Murakami T | Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma. | Digest Dis | 31 | 485-489 | 2013 |

| | | | | | |
|--|---|----------------|--------|-----------|------|
| <u>Kudo M</u> , Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T, the Osaka Liver Cancer Study Group | Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. | Digest Dis | 31 | 490-498 | 2013 |
| <u>Kudo M</u> | Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma? | Liver Cancer | 2(3-4) | 151-152 | 2013 |
| Sakurai T, <u>Kudo M</u> | Molecular link between liver fibrosis and hepatocellular carcinoma. | Liver Cancer | 2(3-4) | 365-366 | 2013 |
| <u>Kudo M</u> , Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T | JSUM ultrasound elastography practice guidelines: liver. | J Med Ultrason | 40 | 325-357 | 2013 |
| Kagawa Y, Okada M, Yagyu Y, Kumano S, Kanemitsu M, <u>Kudo M</u> , Murakami T | Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphasic fast CT imaging technique. | Acta Radiol | 54 | 843-850 | 2013 |
| Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, <u>Kudo M</u> , Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, the Liver Cancer Study Group of Japan | Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. | Brit J Cancer | 109 | 1904-1907 | 2013 |
| Cheng AL, Kang YK, Lin DY, Park JW, <u>Kudo M</u> , Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzalone S, Yang L, Lechuga MJ, Raymond E, for the SUN1170 HCC Study Group | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. | J Clin Oncol | 10; 31 | 4067-4075 | 2013 |
| Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Avina JR, <u>Kudo M</u> , Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL | Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3 BRISK-FL study. | J Clin Oncol | 1; 31 | 3517-3524 | 2013 |

| | | | | | |
|---|---|--------------------|-------|-----------|------|
| Llovet JM, Decaens T, Raoul JL, Boucher E, <u>Kudo M</u> , Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW | Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib failed results from the randomized phase 3 BRISK-PS study. | J Clin Oncol | 1; 31 | 3509-3516 | 2013 |
| Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ | GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. | Int J Clin Pract | | 1-9 | 2013 |
| Nishida N, <u>Kudo M</u> , Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A | Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. | Plos One | 8(9) | e72312 | 2013 |
| Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, <u>Kudo M</u> | Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. | J Med Ultrason | 28 | 15-19 | 2012 |
| Kitano M, <u>Kudo M</u> , Yamao K, Takagi T, Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, Murakami T, Takeyama Y | Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography. | Am J Gastroenterol | 107 | 303-310 | 2012 |
| Sakamoto H, Kimura H, Sekijima M, Matsumoto K, Arao T, Chikugo T, Yamada Y, Kitano M, Ito A, Takeyama Y, <u>Kudo M</u> , Nishio K | Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. | Jpn J Clin Oncol | 42 | 105-112 | 2012 |

| | | | | | |
|---|---|-----------------|----|----------|------|
| Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, Abecassis M, Balabaud C, Barritt GJ, Belghiti J, Bhoori S, Bossuyt P, Breitenstein S, Broelsch C, Bruix J, Burra P, Burroughs A, Busuttil R, Charlton M, Cherqui D, Colombo ML, d'Albuquerque C, D'Alessandro A, de Santibanez EJ, Dufour F, Durand F, Dutkowski P, Duvoux C, El-Serag H, Fan ST, Finn RS, Fisher R, Forner A, Freeman R, Fung J, Geier A, Germani G, Gores G, Gouw AS, Grant D, Greig P, Gurusamy K, Hanto D, Heaton N, Heim M, Hemming A, Hippen B, Hisham A, Hubscher S, Ichida T, Kahn D, Kew M, Kita Y, Kiuchi T, Klintmalm GB, Kneteman N, Kojiro M, <u>Kudo M</u> , Langer B, Lee JM, Lee SG, Lencioni R, Lerut J, Lesurtel M, Livraghi T, Llovet JM, Lo CM, Lodge P, | Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. | Lancet Oncol | 13 | e11-22 | 2012 |
| Minami Y, Kitai S, <u>Kudo M</u> | Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation. | Eur J Radiol | 81 | e277-280 | 2012 |
| Watanabe T, Yamashita K, Fujikawa S, Sakurai T, <u>Kudo M</u> , Shiokawa M, Kodama Y, Uchida K, Okazaki K, Chiba T | Involvement activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. | Arthritis Rheum | 64 | 914-924 | 2012 |
| Takayasu K, Ariei S, <u>Kudo M</u> , Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M | Supersselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. | J Hepatol | 56 | 886-892 | 2012 |

| | | | | | |
|---|--|----------------------------|-------------|------------|------|
| <u>Kudo M</u> , Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O | Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system. | Clin Drug Invest | 32;suppl .2 | 37-51 | 2012 |
| <u>Kudo M</u> | Closing remarks. | Clin Drug Invest | 32;suppl .2 | 52 | 2012 |
| Saito J, Kim SR, <u>Kuod M</u> , Imoto S, Ando K, Nakajima T, Fukuda K, Otono Y, Kim SK, Komaki T, Yano H, Nakashima O, Sugimoto K, Matsuoka T | Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography. | Intern Med | 51 | 885-890 | 2012 |
| Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA | First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. | Int J Clin Pract | 66 | 675-683 | 2012 |
| Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, <u>Kudo M</u> , Murakami T | Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ? | Hepatob Pancreatic Dis Int | 11 | 307-313 | 2012 |
| <u>Kudo M</u> | Welcome to the first issue of Liver Cancer. | Liver Cancer | 1(1) | 1 | 2012 |
| Hagiwara S, <u>Kudo M</u> , Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T | Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma. | Brit J Cancer | 106 | 1997-2003 | 2012 |
| Shiina T, Maki T, Yamakawa M, Mitake T, <u>Kudo M</u> , Fujimoto K | Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging. | Jpn J Appl Phys | 51 | 07GF11-1-8 | 2012 |
| Tsuji Y, Watanabe T, <u>Kudo M</u> , Arai H, Strober W, Chiba T | Sensing of commensal organisms by the intracellular sensor NOD1 Mediates experimental pancreatitis. | Immunity | 37 | 326-338 | 2012 |
| Sakamoto H, Kitano M, Kamata K, Miyata T, Kadosaka K, Imai H, Takeyama Y, <u>Kudo M</u> | Transcatheter endoscopy for pancreaticobiliary duct diseases (with videos). | Gastrointest Endosc | 76 | 892-899 | 2012 |
| Takahashi K, Kashida H, <u>Kudo M</u> | Hepatic nodules associated with an inferior mesenteric arteriovenous malformation. | Internal Med | 51 | 2753-2755 | 2012 |

| | | | | | |
|---|---|----------------------|------|-----------|------|
| <u>Kudo M</u> | Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? | Liver Cancer | 1(2) | 59-60 | 2012 |
| <u>Kudo M</u> | Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. | Liver Cancer | 1(2) | 62-70 | 2012 |
| Park AM, <u>Kudo M</u> , Hagiwara S, Tabuchi M, Watanabe T, Munakata H, Sakurai T | p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expression. | Free Radical Bio Med | 52 | 2284-2291 | 2012 |
| Sakurai T, Kashida H, <u>Kudo M</u> | Case of Peutz-Jeghers syndrome with depressed-type early duodenal carcinoma. | Digest Endosc | 24 | 489 | 2012 |
| <u>Kudo M</u> | Preface. | Digest Dis | 30 | 539-540 | 2012 |
| Hagiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, <u>Kudo M</u> | Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. | Digest Dis | 30 | 541-546 | 2012 |
| Nishida N, Arizumi T, Hayaishi S, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ikai I, <u>Kudo M</u> | Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. | Digest Dis | 30 | 547-553 | 2012 |
| Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsunami H, Izumi N, <u>Kudo M</u> , for RE TRY study group | Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy. | Digest Dis | 30 | 554-560 | 2012 |
| Hagiwara S, Sakurai T, Takita M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Nagai T, Hayaishi S, Arizumi T, Nishida N, <u>Kudo M</u> | Risk of HCC development in cases of hepatitis C treated by long-term, low-dose PEG-IFN α 2a. | Digest Dis | 30 | 561-567 | 2012 |

| | | | | | |
|--|--|-------------------------------|----|-----------|------|
| Kobayashi S, Kim SR, Imoto S, Ando K, Hirakawa M, Saito J, Fukuda K, Otono Y, Sakaki M, Tsuchida S, Kim SK, Hayashi Y, Nakano M, <u>Kudo M</u> | Histopathological diagnosis of early HCC through biopsy -efficacy of victoria blue and cytokeratin 7 staining-. | Digest Dis | 30 | 574-579 | 2012 |
| Tsuchida S, Fukumoto T, Toyokawa A, Awazu M, Kusunoki N, Kido M, Takahashi M, Tanaka M, Kuramitsu K, Kim SR, <u>Kudo M</u> , Ku Y | Novel non-trocar technique for laparoscopic radiofrequency ablation. | Digest Dis | 30 | 588-591 | 2012 |
| Minami Y, <u>Kudo M</u> | Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. | Digest Dis | 30 | 592-597 | 2012 |
| <u>Kudo M</u> , Ueshima K, Arizumi T | Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single center experience. | Digest Dis | 30 | 609-616 | 2012 |
| Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, <u>Kudo M</u> , Murakami T | Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. | Eur J Radiol | 81 | 1460-1464 | 2012 |
| Nishida N, <u>Kudo M</u> , Nagasaka T, Ikai I, Goel A | Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. | Hepatology | 56 | 994-1003 | 2012 |
| Kitano M, Sakamoto H, <u>Kudo M</u> | Endoscopic ultrasound: contrast enhancement. | Gastrointest Endosc Clin N Am | 22 | 349-358 | 2012 |
| <u>Kudo M</u> | Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. | World J Gastroenterol | 18 | 6005-6017 | 2012 |
| Inoue T, Kitai S, Hayaishi S, <u>Kudo M</u> | Septicemia due to vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patient. | Clin J Gastroenterol | 5 | 383-387 | 2012 |

| | | | | | |
|---|--|----------------------|------|-----------|------|
| <u>Kudo M</u> | Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. | Liver Cancer | 1(3) | 141-143 | 2012 |
| Okusaka T, Kasugai H, Ishii H, <u>Kudo M</u> , Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K | A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. | Invest New Drug | 30 | 2015-2025 | 2012 |
| Hagiwara S, <u>Kudo M</u> , Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T | Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. | Hepatol Res | 42 | 394-400 | 2012 |
| Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M | p38 α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. | Cancer Res | 73 | 215-224 | 2012 |
| <u>Kudo M</u> | Targeted therapy for liver cancer: updated review in 2012. | Curr Cancer Drug Tar | 12 | 1062-1072 | 2012 |
| Kaneko S, Furuse J, <u>Kudo M</u> , Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y | Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. | Hepatol Res | 42 | 523-542 | 2012 |
| Inoue T, <u>Kudo M</u> , Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T | Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and Dysplastic nodule and comparison of detection sensitivity versus MDCT. | J Gastroenterol | 47 | 1036-1047 | 2012 |

| | | | | | |
|---|---|----------------------|-----|-----------|------|
| Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, <u>Kudo M</u> , Nishio K | Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. | Mol Cancer Ther | 10 | 169-177 | 2011 |
| <u>Kudo M</u> , Hatanaka K, Kumada T, Toyoda H, Tada T | Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. | Am J Gastroenterol | 106 | 368-370 | 2011 |
| Kudo K, Arao T, Tanaka K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, Velasco M, Fujita Y, Saijo N, <u>Kudo M</u> , Nishio K | Antitumor activity of BIBF 1120, a vascular endothelial growth factor-2 inhibitor and use of VEGFR2+pTYR+leucocyte as a pharmacodynamic biomarker. | Clin Cancer Res | 17 | 1373-1381 | 2011 |
| Hagiwara S, <u>Kudo M</u> , Ueshima K, Chung H, Yamaguchi M, Takita M, Hagi S, Kimura M, Arao T, Nishio K, Park AM, Munakata H | The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+pegylated interferon α -2b therapy against advanced hepatocellular carcinoma. | J Gastroenterol | 46 | 212-221 | 2011 |
| Sakamoto H, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, Dote K, <u>Kudo M</u> | Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS. | Gastrointest Endosc | 73 | 227-237 | 2011 |
| Kagawa Y, Okada M, Kumano S, Katsube T, Imaoka I, Tanigawa N, Ishii K, <u>Kudo M</u> , Murakami T | Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. | J Magn Reson Imaging | 33 | 864-872 | 2011 |
| Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, <u>Kudo M</u> | Management of hepatitis B: Consensus of Japan Society of Hepatology 2009. | Hepatol Res | 41 | 1-21 | 2011 |
| Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, <u>Kudo M</u> , Kitagaki H, Murakami T | Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. | Invest Radiol | 46 | 277-283 | 2011 |
| <u>Kudo M</u> , Yamao K, Shimosegawa T | The prognosis of patients with pancreatic cancer is extremely poor. Prefece. | Pancreatol | 11 | 1-2 | 2011 |

| | | | | | |
|--|--|----------------|------|-----------------|------|
| Sakurai T, <u>Kudo M</u> , Fukuta N, Nakatani T, Kimura M, Park AM, Munakata H | Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. | Pancreatol ogy | 11 | 7-13 | 2011 |
| Kitano M, <u>Kudo M</u> , Sakamoto H, Komaki T | Endoscopic ultrasonography and contrast-enhanced endoscopic. | Pancreatol ogy | 11 | 28-33 | 2011 |
| Komaki T, Kitano M, Sakamoto H, <u>Kudo M</u> | Endoscopic ultrasonography-guided biliary drainage: evaluation of a choledochoduodenostomy technique. | Pancreatol ogy | 11 | 47-51 | 2011 |
| Sakamoto H, Kitano M, Komaki T, Imai H, Kamata K, <u>Kudo M</u> | Endoscopic ultrasound-guided neurolysis in pancreatic cancer. | Pancreatol ogy | 11 | 52-58 | 2011 |
| Minami Y, <u>Kudo M</u> | Radiofrequency ablation of hepatocellular carcinoma: A literature review. | Int J Hepatol | 2011 | 9pages (104685) | 2011 |
| Eguchi S, Kanematsu T, Arii S, Omata M, <u>Kudo M</u> , Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M, for the Liver Cancer Study Group of Japan | Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. | Brit J Surg | 98 | 552-557 | 2011 |
| Kitano M, Sakamoto H, Komaki T, <u>Kudo M</u> | New techniques and future perspective of EUS for the differential diagnosis of pancreatic malignancies; Contrast harmonic imaging. | Digest Endosc | 23 | 46-50 | 2011 |
| <u>Kudo M</u> | Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. | Digest Dis | 29 | 273-277 | 2011 |
| <u>Kudo M</u> | Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. | Digest Dis | 29 | 289-302 | 2011 |
| <u>Kudo M</u> | mTOR inhibitor for the treatment of hepatocellular carcinoma. | Digest Dis | 29 | 310-315 | 2011 |
| <u>Kudo M</u> | Future treatment option for hepatocellular carcinoma: a focus on brivanib. | Digest Dis | 29 | 316-320 | 2011 |

| | | | | | |
|--|--|-------------------------|----|-----------|------|
| Ueshima K, <u>Kudo M</u> , Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T: | Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of Soraenib for hepatocellular carcinoma. | Digest Dis | 29 | 321-325 | 2011 |
| Hayaishi S, Chung H, <u>Kudo M</u> , Ishikawa E, Takita M, Ueada T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K | Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. | Digest Dis | 29 | 326-332 | 2011 |
| <u>Kudo M</u> , Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M | Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version. | Digest Dis | 29 | 339-364 | 2011 |
| Yoshida H, Shiratori Y, <u>Kudo M</u> , Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuiji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Hokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M | Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. | Hepatology | 54 | 532-540 | 2011 |
| Chung H, Watanabe T, <u>Kudo M</u> , Chiba T | Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. | J Viral Hepat | 18 | e561-567 | 2011 |
| Kashida H, Ikehara N, Hamatani S, Kudo SE, <u>Kudo M</u> | Endoscopic characteristics of colorectal serrated lesions. | Hepato gastroenterology | 58 | 1163-1167 | 2011 |

| | | | | | |
|---|--|------------------|----|-----------|------|
| <u>Kudo M</u> , Imanaka K, Chiba N, Nakachi K, Tak WT, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K | Phase III study of Sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. | Eur J Cancer | 47 | 2117-2127 | 2011 |
| Llovet JM, Paradis V, <u>Kudo M</u> , Zucman-Rossi J | Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. | Liver Transplant | 17 | S67-71 | 2011 |
| <u>Kudo M</u> | Tailor-made therapy for viral hepatitis: Recent advances. | Digestion | 84 | 1-4 | 2011 |
| Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, <u>Kudo M</u> | Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load. | Digestion | 84 | 5-9 | 2011 |
| Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasaegawa Y, Fujinami A, Ohta M, Ei-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, <u>Kudo M</u> | ouble-filtration plasmapheresis plus interferon- β for HCV-1b patients with non-sustained virological response to previous combination therapy. | Digestion | 84 | 10-16 | 2011 |
| Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, <u>Kudo M</u> | Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study. | Digestion | 84 | 43-49 | 2011 |
| Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, <u>Kudo M</u> | Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. | Digestion | 84 | 56-61 | 2011 |

| | | | | | |
|--|--|-----------|----|---------|------|
| <u>Kudo M</u> | Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy. | Oncology | 81 | 1-10 | 2011 |
| Sakurai T, <u>Kudo M</u> | Signaling pathways governing tumor angiogenesis. | Oncology | 81 | 24-29 | 2011 |
| Sakurai T, <u>Kudo M</u> , Itoh K, Ryu U, Higashitsuji H, Fujita J | Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells. | Oncology | 81 | 30-35 | 2011 |
| <u>Kudo M</u> | Adjuvant therapy after curative treatment for hepatocellular carcinoma. | Oncology | 81 | 50-55 | 2011 |
| Alaboudy A, Inoue T, Hatanak K, Chung H, Hyodo T, Kumano S, Murakami T, Moustafa EFA, <u>Kudo M</u> | Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography. | Oncology | 81 | 66-72 | 2011 |
| <u>Kudo M</u> | Diagnostic imaging of hepatocellular carcinoma: Recent progress. | Oncology | 81 | 73-85 | 2011 |
| Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, Saito S, Kita R, Kimura T, Osaki Y, <u>Kudo M</u> | Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with Sorafenib: A case report. | Oncology | 81 | 152-157 | 2011 |
| Han KH, <u>Kudo M</u> , Ye SL, Choi JY, Poon RTP, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL | Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. | Oncology | 81 | 158-164 | 2011 |
| Kim SR, Yang J, <u>Kudo M</u> , Hino O | Recent advances in the management of chronic hepatitis B. | Hepat Mon | 11 | 601-611 | 2011 |

| | | | | | |
|--|---|-------------------------|----------|-------------|------|
| Minami Y, <u>Kudo M</u> | Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. | World J Gastroenterol | 17 | 4952-4959 | 2011 |
| Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T | the Liver Cancer Study Group of Japan: Demonstration of quality of care measurement using the Japanese liver cancer registry. | Hepatol Res | 41 | 1208-1215 | 2011 |
| Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, <u>Kudo M</u> , Mizokami M, Sakamoto A | Phenotype-dependent production of des- γ -carboxy prothrombin in hepatocellular carcinoma. | J Gastroenterol | 46 | 1219-1229 | 2011 |
| Bridges JF, Joy SM, Gallego G, <u>Kudo M</u> , Ye SL, Han KH, Cheng AL, Blauvelt BM | Needs for hepatocellular carcinoma control policy in the Asia-pacific region. | Asian Pac J Cancer Prev | 12 | 2585-91 | 2011 |
| Bridges JF, Gallego G, <u>Kudo M</u> , Okita K, Han KH, Ye SL, Blauvelt BM | Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. | BMC Health Serv Res | Nov | 298 (12p) | 2011 |
| Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Nozaki Y, Nagata N, <u>Kikuchi Y</u> , Yanase M, Oka S. | Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. | PLOS ONE | Volume 9 | e87596 | 2014 |
| Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Tokunaga K, Mizokami M, Izumi N. | Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C | J Med Virol | 85 (3) | 449-458 | 2013 |
| Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N. | Deep-Sequencing Analysis of the Association between the Quasispecies Nature of the Hepatitis C Virus Core Region and Disease Progression | J. Virol. | 87 | 12541-12551 | 2013 |
| Shindo H, Maekawa S, Komase K, Miura M, Sueki K, Komatsu K, Shindo K, Amemiya F, Nakayama T, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N | IL28B(IFN- λ 3)and IFN- α synergistically inhibit HCV replication. | J Viral hepatitis | 20 (4) | 281-289 | 2013 |

| | | | | | |
|--|--|--|--------|-----------|------|
| Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Sugauchi F, Sakamoto N, Yatsuhashi H, Izumi N | Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. | Antiviral Therapy | 17 | 35-43 | 2012 |
| Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, <u>Sakamoto M</u> , Okada S, Enomoto N | Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. | Hepatol Int | 6 | 386-396 | 2012 |
| Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N | Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. | Hepatol Int | 6 | 386-396 | 2012 |
| Osada M, Kaneko M, <u>Sakamoto M</u> , Endoh M, Takigawa K, Inoue-Suzuki K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y | Causes of thrombocytopenia in chronic hepatitis C viral infection. | Clinical and Applied Thrombosis / Hemostasis | 18 | 272-280 | 2012 |
| Kurosaki M, Hiramatsu N, <u>Sakamoto M</u> , Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, Izumi N | Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. | J Hepatol | 56 (3) | 602-608 | 2012 |
| Maekawa S, <u>Sakamoto M</u> (equally contributed), Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N | Comprehensive analysis for viral elements and IL28B polymorphisms in response to peginterferon plus ribavirin therapy in HCV-1b infection. | Hepatology | 56 | 1611-1621 | 2012 |
| Sueki R, Maekawa S, Miura M, Kadokura M, Komase K, Shindo H, Kanayama A, Ohmori T, Shindo K, Amemiya F, Nakayama Y, Uetake T, Inoue T, <u>Sakamoto M</u> , Enomoto N | Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection. | J Med Virol | 84 | 1360-1368 | 2012 |
| Komase K, Maekawa S, Miura M, Miura M, Sueki R, Kadokura M, Shindo H, Shido K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N. | The serum RANTES level influences the response to pegylated-interferon and ribavirin therapy in chronic hepatitis C. | Hepatology Research | 43 | 865-875 | 2012 |

| | | | | | |
|---|--|------------------|--------|-----------|------|
| Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N. | Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. | Plos One | 6(9) | e24514 | 2011 |
| Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Sugauchi F, Tamori A, Matsuura K, Izumi N. | Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: Decision-tree analysis. | J Gastroenterol | 46 | 1111-1119 | 2011 |
| Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugauchi M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. | Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. | J Hepatol | 54 | 439-448 | 2011 |
| Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, <u>Sakamoto M</u> , Nakagawa M, Sakamoto N, Watanabe M, Enomoto N | Analysis of the complete open reading frame of hepatitis C virus genotype 2a infection reveals critical site influencing the response to peginterferon and ribavirin therapy. | Hepatol Int | 5(3) | 789-799 | 2011 |
| Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N | Sequences in the Interferin Sensitivity Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to Peg-interferon Plus Ribavirin: Data Mining Analysis. | J Med Virol | 83 | 445-452 | 2011 |
| Kurosaki M, Sakamoto N, Iwasaki M, <u>Sakamoto M</u> , Suzuki Y, Hiramatsu N, Sugauchi F, Yatsushashi H, Izumi N. | Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. | J Gastroenterol | 46 | 401-409, | 2011 |
| 坂本穰、榎本信幸 | C型肝炎治療における宿主因子とウイルス因子 - 実地診療での臨床応用のすすめかた | Medical Practice | 30 (2) | 323-328 | 2013 |
| 坂本穰、榎本信幸 | C型肝炎硬変における抗ウイルス療法 | Modern physician | 33 (4) | 454-458 | 2013 |
| 坂本穰、榎本信幸 | ウイルス変異と宿主ゲノムからみたインターフェロン療法の治療成績と発癌リスクを考慮した新規治療法への展望 | 消化器内科 | 56 (4) | 437-442 | 2013 |

| | | | | | |
|---|---|------------------|---------|-----------|------|
| 坂本穰、榎本信幸 | 発癌リスクと治療反応性を考慮したC型肝炎の最新治療 | 消化器内科 | 57 (3) | 379-384 | 2013 |
| 坂本穰、榎本信幸 | C型肝炎診療up-to-date、発癌リスクと新規治療法 | 診断と治療 | 101 (9) | 1277-1282 | 2013 |
| 坂本穰、榎本信幸 | C型肝炎の自然経過と発癌リスク | 成人病と生活習慣病 | 43 (11) | 1310-1315 | 2013 |
| 坂本穰、榎本信幸 | C型肝炎ウイルスと治療 | HIV感染症とAIDSの治療 | 4 (2) | 55-59 | 2013 |
| 坂本穰、榎本信幸 | プロテアーゼ阻害剤に対する耐性変異と意義 | 肝胆膵 | 67 (6) | 893-898 | 2013 |
| 坂本穰 | B型肝炎のインターフェロン治療：sequential therapyを含めて | Phama Medica | 31 (12) | 49-52 | 2013 |
| 坂本穰、榎本信幸 | C型肝炎と肝臓－発癌リスクとウイルス排除の可能性、特集肝臓診療の最前線－知っておきたい診断・治療の新情報、 | 内科 | 109 (3) | 420-424 | 2012 |
| 坂本穰、榎本信幸 | 抗HCV薬、特集：抗ウイルス薬 | 日本臨床 | 70 (4) | 614-619 | 2012 |
| 坂本穰、榎本信幸 | ウイルス変異と宿主ゲノム解析からみたPEG-IFN+RBV療法とProtease阻害剤の適応 | 消化器内科 | 54 (4) | 454-458 | 2012 |
| 坂本穰、榎本信幸 | C型肝炎の個別化治療－肝臓がんの危険性とウイルス排除の可能性を考慮して－ | Medical Practuce | 29 (6) | 1048-1049 | 2012 |
| 坂本穰、榎本信幸 | ペグインターフェロン＋リバビリン＋テラプレビル併用療法－宿主・ウイルス因子の解析からみた最適な治療－ | 消化器の臨床 | 15 (3) | 249-256 | 2012 |
| 坂本穰、榎本信幸 | C型肝炎のウイルス変異と治療効果 | 総合臨床 | 60 (1) | 19-25 | 2011 |
| 坂本穰、榎本信幸 | ウイルス変異からみたPEG-IFN+RBV療法の治療効果予測 | 肝胆膵 | 62 (2) | 307-313 | 2011 |
| 坂本穰、榎本信幸 | 肝炎診療に必要な遺伝子検査. C型肝炎の遺伝子解析と診療への応用 | Medical Practice | 28 (8) | 1383-1388 | 2011 |
| Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S. | MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. | J Virol | 87 | 5720-86 | 2013 |

| | | | | | |
|--|---|--------------------------|----------|--|------|
| Spaniel C, Honda M, Selitsky SR, Yamane D, <u>Shimakami T</u> , Kaneko S, Lanford RE, Lemon SM. | microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. | PLoS One | 8 | e76867 | 2013 |
| Honda M, Shirasaki T, <u>Shimakami T</u> , Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S. | Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes. | Hepatology | in press | in press | 2013 |
| Posuwan N, Payungporn S, Tangkijvanich P, Ogawa S, Murakami S, Iijima S, Matsuura K, Shinkai N, <u>Watanabe T</u> , Poovorawan Y, Tanaka Y. | Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population. | PLoS One | 9(1) | e86007 | 2014 |
| Matsuura K, <u>Watanabe T</u> , and Tanaka Y. | Role of IL28B for chronic hepatitis C treatment toward personalized medicine. | J Gastroenterol Hepatol. | 29(2) | 241-9 | 2014 |
| Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, <u>Watanabe T</u> , Tanaka Y. | Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. | Liver Int. | in press | doi: 10.1111/liv.12321. PMID: 24102823 | 2013 |
| <u>Watanabe T</u> , Inoue T, Tanoue Y, Maekawa H, Hamada-Tsutsumi S, Yoshiba S, Tanaka Y. | Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0. | J Clin Microbiol. | 51(12) | 4275-4276 | 2013 |
| Shinkai N, Matsuura K, Sugauchi F, <u>Watanabe T</u> , Murakami S, Iio E, Ogawa S, Nojiri S, Joh T, Tanaka Y. | Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance. | J Clin Microbiol | 51 | 3484-3491 | 2013 |
| Wong DK, <u>Watanabe T</u> , Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF. | Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. | PLoS One | 8 | e66920 | 2013 |